Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Chronic Myelomonocytic Leukemia: A Single Institution Experience

Allogeneic hematopoietic cell transplant (alloHCT) is the only potentially curative therapy for CMML. Outcomes after alloHCT for higher-risk CMML remain very poor, with 5-year overall survival (OS) of 27%. Given age, comorbidities, and often advanced disease, patient selection and the optimal timing of transplant can be challenging. We undertook this analysis to investigate our institutional experience with alloHCT for CMML.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 136 Source Type: research